369 related articles for article (PubMed ID: 16002927)
21. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
22. CD5 expression in thymic carcinoma.
Hishima T; Fukayama M; Fujisawa M; Hayashi Y; Arai K; Funata N; Koike M
Am J Pathol; 1994 Aug; 145(2):268-75. PubMed ID: 7519823
[TBL] [Abstract][Full Text] [Related]
23. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
[TBL] [Abstract][Full Text] [Related]
25. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
26. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
27. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence.
Marx A; Rieker R; Toker A; Länger F; Ströbel P
Thorac Surg Clin; 2011 Feb; 21(1):25-31. v-vi. PubMed ID: 21070984
[TBL] [Abstract][Full Text] [Related]
28. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
29. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
30. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase receptor expression in thymomas.
Henley JD; Cummings OW; Loehrer PJ
J Cancer Res Clin Oncol; 2004 Apr; 130(4):222-4. PubMed ID: 14762710
[TBL] [Abstract][Full Text] [Related]
32. CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.
Angirekula M; Chang SY; Jenkins SM; Greipp PT; Sukov WR; Marks RS; Olivier KR; Cassivi SD; Roden AC
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565429
[TBL] [Abstract][Full Text] [Related]
33. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
34. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
Tateyama H; Eimoto T; Tada T; Hattori H; Murase T; Takino H
Am J Clin Pathol; 1999 Feb; 111(2):235-40. PubMed ID: 9930146
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
37. Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and immunohistochemical study of 8 cases.
Kalhor N; Moran CA
Hum Pathol; 2019 Apr; 86():124-128. PubMed ID: 30537491
[TBL] [Abstract][Full Text] [Related]
38. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
40. Proliferative activity and apoptosis in thymic epithelial neoplasms.
Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
